Namenda (Memantine): A cure for Alzheimer's Disease?
Namemda- An Introduction to the newest Alzheimer’s medication:
(Memantine) was approved by the FDA in October as the newest treatment
option for sufferers of Alzheimer’s disease. Memantine is marketed in
the United States by Forest Laboratories and will be sold under the
brand name of the Namenda, for patients with moderate to severe
Alzheimer’s Disease. Forest Laboratories has stated that Namenda
should be on the pharmacy shelves in January, 2004. Namenda has
been sold for quite some time in Germany and Canada, and many U.S.
families have been purchasing it over the internet for awhile. It is
estimated that approximately 4 million Americans have Alzheimer’s
disease, and about one million of them are believed to suffer severe
symptoms. This will be the first time in which a medication is being
offered for patients in the moderate to severe stage of the disease.
How will Namenda help?
Namenda has been found to help improve the memories and thinking
skills of some patients who have moderate to severe impairments in
their cognition (ability to think). However for the vast majority, the
drug has been found to slow the pace of deterioration, allowing some
patients to maintain their abilities to function somewhat
independently for a longer period of time, which may benefit the
patient and caregivers in some very important ways.
How is Namenda different from other Alzheimer’s medications?
While there are a few similarities between Namenda and other
Alzheimer’s medications currently on the market, there are many more
differences. Namenda is similar in that like the other Alzheimer’s
medications (Aricept, Exelon, Reminyl and Cognex) it does not usually
improve functioning as much as it retards the deterioration, allowing
individuals to maintain independent functioning for a longer period of
time. The most prominent difference is that these other medications
are known to only be effective in the early stages of the disease,
while Namenda is the first to have demonstrated effectiveness in
the moderate to severe stages of Alzheimer’s. These other drugs delay
the breakdown of another brain chemical called acetylcholine, which is
necessary in the communication between nerve cells. Namenda
naturally blocks excess amounts of another brain chemical called
glutamate, which has been found to damage or kill nerve cells.
Ultimately, doctors may eventually be able to prescribe combinations
of medications in the hopes of better results.
Why should we feel hopeful about Namenda?
just mentioned, doctor’s may be able to possibly use Aricept, Exelon,
Reminyl or Cognex in the early stage the disease and possibly
transition to a medication such as Namenda as the disease progresses
to a more severe level of disability. It is recommended by the FDA’s
scientific advisors whom have evaluated the drug, to recognize that
Namenda does not offer miraculous benefits, and should not be a
source of false hope to families of the most severely ill patients
with Alzheimer’s. However, it is just another step in the progression
of the development of medications which forestall the progressive
deterioration of memory, and eventually may be an avenue toward a
Information adapted from
The PDR Pocket Guide to Prescription Drugs
Namenda picture by permission of
(See additional pictures and dosages)
Additional Information and
webpage by Paul Susic MA Licensed
Psychologist Ph.D. Candidate
Page on Google Plus